AIM： To explore mutations around the interferon sensitivity-determining region （ISDR） which are associated with the resistance of hepatitis C virus lb （HCV-lb） to interferon-α treatment. METHODS： Thirty-seven H...AIM： To explore mutations around the interferon sensitivity-determining region （ISDR） which are associated with the resistance of hepatitis C virus lb （HCV-lb） to interferon-α treatment. METHODS： Thirty-seven HCV-lb samples were obtained from Hong Kong patients who had completed the combined interferon-α/ribavirin treatment for more than one year with available response data. Nineteen of them were sustained virological responders, while 18 were non-responders. The amino acid sequences of the extended ISDR （eISDR） covering 64 amino acids upstream and 67 amino acids downstream from the previously reported ISDR were analyzed. RESULTS： One amino acid variation （I2268V, P = 0.023） was significantly correlated with treatment outcome in this pilot study with a limited number of patients, while two amino acid variations （R2260H, P = 0.05 and $2278T, P = 0.05） were weakly associated with treat- ment outcome. The extent of amino acid variations within the ISDR or eISDR was not correlated with treat- ment outcome as previously reported. CONCLUSION： Three amino acid mutations near but outside of ISDR may associate with interferon treatment resistance of HCV-lb patients in Hong Kong.展开更多
基金Supported by The National Key Technology Research and Development Program of China, No. 2009ZX10004-104
文摘AIM： To explore mutations around the interferon sensitivity-determining region （ISDR） which are associated with the resistance of hepatitis C virus lb （HCV-lb） to interferon-α treatment. METHODS： Thirty-seven HCV-lb samples were obtained from Hong Kong patients who had completed the combined interferon-α/ribavirin treatment for more than one year with available response data. Nineteen of them were sustained virological responders, while 18 were non-responders. The amino acid sequences of the extended ISDR （eISDR） covering 64 amino acids upstream and 67 amino acids downstream from the previously reported ISDR were analyzed. RESULTS： One amino acid variation （I2268V, P = 0.023） was significantly correlated with treatment outcome in this pilot study with a limited number of patients, while two amino acid variations （R2260H, P = 0.05 and $2278T, P = 0.05） were weakly associated with treat- ment outcome. The extent of amino acid variations within the ISDR or eISDR was not correlated with treat- ment outcome as previously reported. CONCLUSION： Three amino acid mutations near but outside of ISDR may associate with interferon treatment resistance of HCV-lb patients in Hong Kong.
